Developing tools to edit genes related to opioid addiction
Epigenome Editing in Opioid Action
This study is exploring new ways to use CRISPR technology to change genes linked to opioid addiction, focusing on how certain brain cells respond to opioids like fentanyl, with the hope of finding better treatments for people struggling with opioid use disorder.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11119188 on NIH RePORTER |
What this research studies
This research focuses on creating advanced CRISPR tools that can specifically target and edit genes involved in opioid addiction and dependence. By understanding how certain brain cells react to opioids, the researchers aim to identify the molecular changes that lead to addiction. The project involves studying specific neuron types in the brain of animals that have been exposed to fentanyl, a potent synthetic opioid, to uncover disrupted gene networks. Ultimately, the goal is to develop precise methods to modify gene activity in these neurons, potentially leading to new treatments for opioid use disorder.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with opioid use disorder or those at risk of developing such conditions.
Not a fit: Patients who do not have a history of opioid use or are not affected by opioid addiction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that more effectively address opioid addiction and reduce the associated health crises.
How similar studies have performed: Other research has shown promise in using CRISPR technology for gene editing, but this specific approach targeting opioid addiction is relatively novel.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Lobo, Mary Kay — University of Maryland Baltimore
- Study coordinator: Lobo, Mary Kay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.